Use of the lidocaine patch 5% in reducing intensity of various pain qualities reported by patients with low-back pain

SUMMARY Objective: To determine the impact of the lidocaine patch 5% on pain qualities associated with low-back pain (LBP) through use of the Neuropathic Pain Scale (NPS). Patients and methods: Patients were enrolled in an open-label, non-randomized, prospective, 6-week study involving 8 clinical trial sites in the United States. Eligible patients had non-radicular LBP and reported moderate-to-severe pain on the NPS at study enrollment. Patients were stratified to 3 groups based on the duration of their LBP, defined as acute/sub-acute (< 3 months), short-term chronic (3–12 months), or long-term chronic LBP (> 12 months). The lidocaine patch 5% was applied to the area of maximal pain, using no more than a total of 4 patches changed every 24 h. Effectiveness was measured by change from baseline to Week 2 and Week 6 in 4 composite measures of the NPS: NPS-10, NPS-4, NPS-8, and NPS-non-allodynia. Safety was assessed by adverse events (AEs), dermal assessment of application site(s), and skin sensory testing. Results: In the combined patient population (n = 71), 6 weeks of treatment with lidocaine patch 5% significantly improved all 4 NPS composite measures at both Week 2 and Week 6 ( p < 0.001). Separate analyses by subgroups revealed differential improvements in the 4 composite measures. Eleven patients (15.5%) experienced treatment-related AEs that were primarily mild-to-moderate and dermal in nature. Conclusions: In patients with moderate-to-severe LBP, 2 weeks and 6 weeks of treatment with the lidocaine patch 5% significantly reduces the intensity of pain qualities as measured by all 4 NPS composite measures. Lidocaine patch 5% is well tolerated with few systemic AEs and may provide beneficial pain relief for patients receiving multidisciplinary treatment without increasing risks for adverse drug interactions. Pain scales such as the NPS offer the ability to measure various pain qualities experienced by LBP patients and may allow clinicians to assess the treatment impact of different medications.

[1]  C. Argoff.  New Analgesics for Neuropathic Pain: The Lidocaine Patch , 2000, The Clinical journal of pain.

[2]  M. Weinblatt.  Drug interactions with non steroidal anti-inflammatory drugs (NSAIDs). , 1989, Scandinavian journal of rheumatology. Supplement.

[3]  A. Woolf,et al.  Burden of major musculoskeletal conditions. , 2003, Bulletin of the World Health Organization.

[4]  M. Rowbotham,et al.  Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia , 1996, Pain.

[5]  M. Perazella,et al.  Selective cyclooxygenase-2 inhibitors: a pattern of nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs. , 2001, The American journal of medicine.

[6]  M. Drass,et al.  Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain. , 2003, Pain medicine.

[7]  V Putz-Anderson,et al.  Back pain among workers in the United States: national estimates and workers at high risk. , 1995, American journal of industrial medicine.

[8]  H. Tropp,et al.  Can a pharmacological pain analysis be used in the assessment of chronic low back pain? , 2004, European Spine Journal.

[9]  R. Deyo,et al.  Drug Therapy for Back Pain: Which Drugs Help Which Patients? , 1996, Spine.

[10]  K. Palmer,et al.  Back pain in Britain: comparison of two prevalence surveys at an interval of 10 years , 2000, BMJ : British Medical Journal.

[11]  J. Lidbeck.  Central hyperexcitability in chronic musculoskeletal pain: a conceptual breakthrough with multiple clinical implications. , 2002, Pain research & management.

[12]  Jun-Ming Zhang,et al.  Decreasing sympathetic sprouting in pathologic sensory ganglia: a new mechanism for treating neuropathic pain using lidocaine , 2004, Pain.

[13]  B. Lee,et al.  Sympathetic sprouting in the dorsal root ganglia of the injured peripheral nerve in a rat neuropathic pain model , 1996, The Journal of comparative neurology.

[14]  M. Moskowitz.  Pharmacotherapy of neuropathic low back pain , 2003, Current pain and headache reports.

[15]  J. Rizzo,et al.  The labor productivity effects of chronic backache in the United States. , 1998, Medical care.

[16]  M. Rowbotham,et al.  The Lidocaine Patch 5% Effectively Treats All Neuropathic Pain Qualities: Results of a Randomized, Double-Blind, Vehicle-Controlled, 3-Week Efficacy Study With Use of the Neuropathic Pain Scale , 2002, The Clinical journal of pain.

[17]  J. Bogousslavsky,et al.  Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study , 2003, Pain.

[18]  M. Rowbotham,et al.  Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study , 1999, Pain.

[19]  F. Burch,et al.  Lidocaine patch 5% improves pain, stiffness, and physical function in osteoarthritis pain patients. A prospective, multicenter, open-label effectiveness trial. , 2004, Osteoarthritis and cartilage.

[20]  A. Gammaitoni,et al.  Pharmacokinetics and Tolerability of Lidocaine Patch 5% with Extended Dosing , 2002, The Annals of pharmacotherapy.

[21]  Ricardo Pietrobon,et al.  Estimates and Patterns of Direct Health Care Expenditures Among Individuals With Back Pain in the United States , 2004, Spine.

[22]  C. Pasero.  Lidocaine patch 5%. , 2003, The American journal of nursing.

[23]  Wilfrid Jänig,et al.  Peripheral nerve injury triggers noradrenergic sprouting within dorsal root ganglia , 1993, Nature.

[24]  L. C. Russell,et al.  The effect of intravenous lidocaine, tocainide, and mexiletine on spontaneously active fibers originating in rat sciatic neuromas , 1989, Pain.

[25]  A. J. Carter,et al.  Analgesic activity of a novel use‐dependent sodium channel blocker, crobenetine, in mono‐arthritic rats , 2001, British journal of pharmacology.

[26]  T. Jensen,et al.  Proceedings of the 7th World Congress on Pain , 1997 .

[27]  B. Galer,et al.  Topical lidocaine patch relieves a variety of neuropathic pain conditions: an open-label study. , 2000, The Clinical journal of pain.

[28]  Y. Masubuchi,et al.  Structural requirements for the hepatotoxicity of nonsteroidal anti-inflammatory drugs in isolated rat hepatocytes. , 1998, The Journal of pharmacology and experimental therapeutics.